Charles Nemeroff

Professor and Chair of the Department of Psychiatry and Behavioral Sciences at Dell Medical School, The University of Texas at Austin

Data updated

Papers

5 publications

Trials

0 clinical trials

Links

Research Footprint

Charles Nemeroff appears in 5 tracked papers (2015–2023), most studied alongside Ketamine, Psilocybin and Esketamine, across Depressive Disorders, Major Depressive Disorder (MDD) and Treatment-Resistant Depression (TRD).

Most-cited paper: Synthesizing the Evidence for Ketamine and Esketamine in Treatment-Resistant Depression: An International Expert Opinion on the Available Evidence and Implementation (676 citations).

Frequent co-authors: Gerard Sanacora, Sanjay Mathew and Mark Andrew Frye.

Background & Research

Charles Barnet Nemeroff is an American psychiatrist and neuropsychopharmacology researcher. He earned his medical and doctoral degrees from the University of North Carolina School of Medicine, trained in psychiatry at UNC and Duke, and previously held senior academic leadership roles at Emory University and the University of Miami before joining the University of Texas at Austin.

Key Impact

Charles B. Nemeroff is a highly cited psychiatrist whose work has helped shape modern research and expert opinion on ketamine, esketamine, and emerging psychedelic treatments for mood disorders.

5

Research Papers

View publications →

0

Clinical Trials

Explore trials →

Collaboration Network

20 collaborators· click a node to visit their profile

Full network →

Affiliations

Institutions, companies, and organisations Charles Nemeroff is associated with.